Watson to resume shipment of iron deficiency anemia drug

MORRISTOWN, N.J. A drug that had been out of stock due to changes in the manufacturing site and raw material supply issues has resumed shipment, the drug’s manufacturer announced Friday.

Watson Pharmaceuticals said the intravenous iron-replacement therapy INFeD (iron dextran injection USP) was re-entering the market earlier than expected.

The drug is used to treat patients with iron deficiency anemia for whom oral treatments are unsatisfactory or impossible.